10 June 2019 - Deborah Wilkes
Sanofi has announced that Paul Hudson will replace Olivier Brandicourt as chief executive officer from 1 September 2019.
The French company said Brandicourt, who has been chief executive officer since 2 April 2015, had "decided to retire".
Paul Hudson is chief executive officer of Novartis Pharmaceuticals and a member of the Executive Committee of Novartis. Before joining Novartis in 2016, Hudson worked for AstraZeneca and Schering-Plough.
Sanofi described Hudson, 51, as a "seasoned leader with a strong international experience, particularly in the US, Japan and Europe".
Serge Weinberg, Sanofi's chairman, said Hudson's "skills and experience give him all the assets he needs to accelerate growth and lead the group's adaptation to new strategic challenges, particularly in the areas of research and development and digital".
Novartis has appointed Marie-France Tschudin – president of the Novartis company Advanced Accelerator Applications (AAA) – as president of Novartis Pharmaceuticals.
Take out an Annual Subscription to the OTCToolbox website, giving you UNLIMITED ACCESS to all of our publications
* Premium News Stories
* OTCToolbox Innovations magazine NEW IDEAS BETTER WAYS
* OTCToolbox Deals Database
* News Extras
* OTC Deal Trends Briefing
* OTC Company Strategies Report
Helping you and your company make well-informed decisions
CLICK HERE TO FIND OUT MORE